Aggregate potential clinical milestone payments available to be earned under collaboration agreement.

No definition available.

Name:	mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration and license agreement entered date.

+ References

No definition available.

+ Details

Name:	mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix:	mgnx_
Data Type:	us-types:dateStringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix:	mgnx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Non-refundable up front payment.

+ References

No definition available.

+ Details

Name:	mgnx_NonRefundableUpFrontPayment
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of annual maintenance payment received.

+ References

No definition available.

+ Details

Name:	mgnx_NumberOfAnnualMaintenancePaymentReceived
Namespace Prefix:	mgnx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of molecules to be developed and commercialized as per collaborations.

+ References

No definition available.

+ Details

Name:	mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations
Namespace Prefix:	mgnx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Research obligation completion date.

+ References

No definition available.

+ Details

Name:	mgnx_ResearchObligationCompletionDate
Namespace Prefix:	mgnx_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information 4 (Detail) (USD $)	1 Months Ended	12 Months Ended
	Oct. 31, 2010 Molecule	Dec. 31, 2014 Payments	Dec. 31, 2013	Dec. 31, 2012
License And Collaboration Agreements [Line Items]
Deferred revenue, Current		$ 14,248,000us-gaap_DeferredRevenueCurrent	$ 20,267,000us-gaap_DeferredRevenueCurrent
Deferred revenue, Long-term liabilities		16,472,000us-gaap_DeferredRevenueNoncurrent	7,136,000us-gaap_DeferredRevenueNoncurrent
Boehringer [Member]
License And Collaboration Agreements [Line Items]
Collaboration agreement date		October 2010
Commercialization of molecules	10
Nonrefundable upfront payment	15,000,000
Number of annual maintenance payments received		3
Clinical milestone payments		41,000,000
Regulatory milestone payments		89,000,000
Sales milestone payments		83,000,000
Research obligation completion date		2015-09
Recognized revenue under agreement		13,700,000	14,400,000	11,700,000
Deferred revenue			12,800,000
Deferred revenue, Current		5,800,000	7,000,000
Deferred revenue, Long-term liabilities			5,800,000
Milestone payment		$ 2,000,000	$ 5,000,000	$ 2,000,000